State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Hepatology. 2013 Feb;57(2):637-47. doi: 10.1002/hep.26083. Epub 2012 Dec 6.
Hepatocellular carcinoma (HCC) is a major liver malignancy. We previously demonstrated that deregulation of epigenetic regulators is a common event in human HCC. Suppressor of variegation 3-9 homolog 1 (SUV39H1), the prototype of histone methyltransferase, is the major enzyme responsible for histone H3 lysine 9 trimethylation, which, essentially, is involved in heterochromatin formation, chromosome segregation, and mitotic progression. However, the implication of SUV39H1 in hepatocarcinogenesis remains elusive. In this study, we found that SUV39H1 was frequently up-regulated in human HCCs and was significantly associated with increased Ki67 expression (P < 0.001) and the presence of venous invasion (P = 0.017). To investigate the role of SUV39H1 in HCC development, both gain- and loss-of-function models were established. SUV39H1 overexpression remarkably enhanced HCC cell clonogenicity, whereas knockdown of SUV39H1 substantially suppressed HCC cell proliferation and induced cell senescence. In addition, ectopic expression of SUV39H1 increased the migratory ability of HCC cells, whereas a reduced migration rate was observed in SUV39H1 knockdown cells. The significance of SUV39H1 in HCC was further demonstrated in a nude mice model; SUV39H1 knockdown drastically inhibited in vivo tumorigenicity and abolished pulmonary metastasis of HCC cells. We also identified microRNA-125b (miR-125b) as a post-transcriptional regulator of SUV39H1. Ectopic expression of miR-125b inhibited SUV39H1 3'-untranslated-region-coupled luciferase activity and suppressed endogenous SUV39H1 expression at both messenger RNA and protein levels. We have previously reported frequent down-regulation of miR-125b in HCC. Interestingly, miR-125b level was found to be inversely correlated with SUV39H1 expression (P = 0.001) in clinical specimens. Our observations suggested that miR-125b down-regulation may account for the aberrant SUV39H1 level in HCC.
Our study demonstrated that SUV39H1 up-regulation contributed to HCC development and metastasis. The tumor-suppressive miR-125b served as a negative regulator of SUV39H1.
肝细胞癌(HCC)是一种主要的肝脏恶性肿瘤。我们之前已经证明,表观遗传调控因子的失调是人类 HCC 的一个常见事件。SUV39H1(组蛋白甲基转移酶的原型)是主要负责组蛋白 H3 赖氨酸 9 三甲基化的酶,它主要参与异染色质形成、染色体分离和有丝分裂进展。然而,SUV39H1 在肝癌发生中的作用仍然难以捉摸。在这项研究中,我们发现 SUV39H1 在人类 HCC 中经常上调,并且与 Ki67 表达增加(P < 0.001)和静脉侵犯的存在显著相关(P = 0.017)。为了研究 SUV39H1 在 HCC 发展中的作用,我们建立了增益和失活模型。SUV39H1 的过表达显著增强了 HCC 细胞的克隆形成能力,而 SUV39H1 的敲低则显著抑制了 HCC 细胞的增殖并诱导细胞衰老。此外,SUV39H1 的异位表达增加了 HCC 细胞的迁移能力,而在 SUV39H1 敲低细胞中观察到迁移率降低。SUV39H1 在 HCC 中的重要性在裸鼠模型中得到了进一步证明;SUV39H1 敲低大大抑制了体内肿瘤生成并消除了 HCC 细胞的肺转移。我们还鉴定了 microRNA-125b(miR-125b)作为 SUV39H1 的转录后调节因子。miR-125b 的异位表达抑制了 SUV39H1 3'-非翻译区偶联的荧光素酶活性,并抑制了内源性 SUV39H1 在信使 RNA 和蛋白质水平的表达。我们之前已经报道了 miR-125b 在 HCC 中的频繁下调。有趣的是,在临床标本中发现 miR-125b 的水平与 SUV39H1 的表达呈负相关(P = 0.001)。我们的观察表明,miR-125b 的下调可能是 HCC 中 SUV39H1 水平异常的原因。
我们的研究表明 SUV39H1 的上调促进了 HCC 的发展和转移。肿瘤抑制 miR-125b 作为 SUV39H1 的负调节剂。